Meta-analysis confirms growth hormone therapy benefits in Prader–Willi syndrome
A meta-analysis confirms growth and body composition benefits for children with Prader–Willi syndrome given recombinant human growth hormone.
Four daily hydrocortisone doses best mimic physiological cortisol profile for CAH patients
Giving hydrocortisone four times daily at a time-varying dose may be the best approach for children with congenital adrenal hyperplasia, say the authors of a pharmaco (P)-kinetic and P-dynamic modelling study.
Day Three: Diabetes genetic risk score aids discovery of novel monogenic subtypes
The type 1 diabetes genetic risk score differentiates between patients with monogenic and polygenic autoimmune diabetes and can thus be used to aid the discovery of novel genes associated with the monogenic form.
Day Three: Gigantism: The importance of FIPA, AIP mutations and X-LAG
Recent developments in the field of pituitary gigantism, including the discovery of a new syndrome and genes related to this syndrome, were presented in a plenary session at the 58th Annual ESPE Meeting in Vienna, Austria.
Day Two: Growth and growth factor research highlights presented at ESPE 2019
Growth hormone therapy in young children with Prader-Willi syndrome, genes linked to isolated short stature, and the role of insulin-like growth factor -2 in autoimmune disease are the subjects of three papers included in the 2019 Yearbook of Paediatric Endocrinology.
Achieving Adherence to Growth Hormone Therapy
Download Martin Savage and Svante Norgren have written a ‘roadmap’ summarising key steps in the initiation of a program to assess and improve adherence. The successful establishment of such a progr […]